CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
8 weeks (±2 weeks) to patients with metastatic castration resistant prostate cancer (mCRPC) in order to assess the safety and effic...
Phase 2
Seoul, Korea, Republic of
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Seoul, Korea, Republic of and 51 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
Seoul, Korea, Republic of and 131 other locations
second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate...
Phase 3
Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of and 33 other locations
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer...
Phase 3
Seoul, Korea, Republic of
plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednison...
Phase 2, Phase 3
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 112 other locations
examination to determine the presence of recurrent or metastatic prostate cancer in patients whose recurrent or metastatic lesions ...
Phase 3
Seoul, Korea, Republic of and 5 other locations
plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the doce...
Phase 3
Seoul, Korea, Republic of and 216 other locations
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Seoul, Korea, Republic of and 388 other locations
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutam...
Phase 2
Seoul, Korea, Republic of and 233 other locations
Clinical trials
Research sites
Resources
Legal